Upload
lekiet
View
217
Download
0
Embed Size (px)
Citation preview
Thermocoagulation as a
treatment of the great
saphenous vein
Dr. S. Thomis, vascular surgeon UZ Leuven Belgium
• Introduction
• Working principle
• Indication/contra-indication
• Procedure
• Postoperative care
• Results pilot study
Introduction
• Varicose veins and chronic venous disease are a very common pathology, around 20-40% of the population
• The last decade a lot of new therapy modalities
• Since 1999:endovenous treatment
– Minimal invasive
– Less complications
Nysten T, van den Bos R, Goldman M et al. Minimally invasive techniques in the treatment
of saphenous varices veins. J Am Acad Dermatol 2008;60(1):110-119
Introduction: endovenous treatment
• RFA
• EVLA
• Foam
• Steam sclerosis
• Chemical ablation: Clarivein, Sapheon
Thermocoagulation: EVRF
Heating of the vein wall
Endothelial destruction:
• Vein contraction
• Fibrotic sealing of the vessel
EVRF by Fcare systems
6
RF signal generation
Disposable catheter or needle
Working Principle
Non-insulated tip
Central unit
EVRF
7 Choice of different disposables adjusted to size of the vein
Small varicose veins and couperose
Varicose veins from 1 to 4 mm
Saphenous veins
Varicose veins from 1 to 4 mm
Small varicose veins and couperose
Saphenous veins
Indications EVRF CR45i
• GSV and SSV reflux with a diameter of 3 to
12 mm
• Not too tortuous or too superficial
• Recurrence GSV: after crossectomie, a
hunterperfo,…
• Big tributaries (vena accessoria)
Contra-indications
• Absolute CI: acute thrombosis
• Relatieve CI:diameter smaller than 3mm and
greater than 15mm, too superficial
Procedure
• Local, spinal or general anaesthesia
• Anti-trendelenburg position
• US guided puncture of the vein at the lowest point of
reflux, usually about 10 cm below the knee/at least
15 cm above the foot for SSV
• 19 gauge needle
• 6Fr sheath
Procedure
• Positioning of the catheter at the groin/knee pit 1.5
tot 2 cm from the SFJ/SPJ, in the groin behind the
ostium of the epigastric vein
• Very flexible catheter
• Injection of tumescent liquid around the vein,
approximately 10cc/cm (for a long GSV around
500cc)
The area between the skin and the catheter needs to
be around 1 cm!
•Catheter
connecting to the
generator.
•Selecting GSV
treatment
Positioning
Positioning
Position of the catheter in a incompetent GSV from a Hunterperfo
Tumescence
Procedure
• Recheck the position of the catheter after applying
tumescent
• Start treatment: retract catheter 0.5 cm every three
beeps, you can adjust the watt according to the
diameter of the vein (normally 25W): for a GSV 250-
300 J/cm
• A marcation on the catheter shows when you need
to retract the sheath
Procedure
Postoperative care
• Compression stockings CCL II for 1 week day and
night, and 2 weeks only in the daytime (when
combined with muller excisions).
• Immediate mobilisation after the treatment
• LMWH profylactic dose only if riskfactors for DVT
• Clinical check-up at 1 week and then a US check at
1 month FU
Postoperative US
EVRF trial
• Single center (UZ Leuven, Belgium)
• pilot study
• 40 GSV were included from 11-2011
until 3-2012
• 1 week clinical FU
• 1 month and 6 month clinical and
duplex FU
Exclusion criteria
- Deep venous insufficiency
- Cross dilatation with more than 2 incompetent side-branches
and maximal diameter of the saphenous vein > 15 mm
- Therapeutically anticoagulation or hypocoagulopathy
- Hypercoagulopathy
- Peripheral arterial occlusive disease
- Pregnancy
- Patients younger than 18 years
EVRF Trial
• Primary endpoint:
– Occlusion rate at 1 month follow up (GELEV-score) and at 6
month follow up
• Secondary endpoints:
– Side effects
• Ecchymosis
• Pain
• Paresthesia
– Analgetic use
– Quality of life
– Patient satisfaction
Results
• Age: mean 50.1 years (SD 14.9)
• Gender: M/V: 12/28
• BMI: mean 25.2 (SD 4.5)
• Profession: standing/sitting: 22/18
• CEAP: mean C: 2.3 (SD 0.9), 34/40
C2
Results
• General/spinal/local:30/2/8
• LMWH: 11/40
• Total energy: mean 7365.8 J
• Length: mean 37.2 cm
• Diameter preop: mean 6.5 mm (SD
1.6)
Analgesia
• Recorded at 1 week and 1 month
• Total number analgetics: 0.7 (SD 1.1)
• Days of analgetics: 0.9 days(SD 1.8)
• Mostly paracetamol or ibuprofen
Ecchymosis
• Ecchymosis score = Area surface of
ecchymosis / length of treated vein
• Measured at 1 week postoperative
• = 0.02 (max of 0.13)
Results
• Periphlebitis: 1.1 days (SD 2.8)
• Paresthesia: 1/40
• Patient satisfaction: 8.9 (SD 1.0)
QOL
• Measured using the CIVIQ2-score
– Quality of life score for lower limb venous
insufficiency
– 20 Questions
– 4 domains: pain, physical, psychological, social
– Higher scores -> lower health related quality of
life
QOL
20
30
40
50
60
70
80
90
100
preop
postop 1W
postop 1M
Painscore: VAS scale
0
1
2
3
4
5
6
7
8
9
10
2 5 7 10
mean
mean
Occlusion rate at 1M and 6M
• Introduced by GELEV – Lev 0: no occlusion, refluxing vein, unchanged vein
– Lev 1a: partial occlusion with proximal reflux
– Lev 1b: partial occlusion without reflux
– Lev 2a: complete occlusion with unchanged or larger diameter
– Lev 2b: complete occlusion with diameter reduction >30%
– Lev 3: complete occlusion with diameter reduction >50%
– Lev 4: fibrotic cord, vein not visible
Occlusion rate
0
5
10
15
20
25
30
35
40
1m 6m
0
1b
2a
2b
3
4
Occlusion rate: 92.5%
• 3 veins were not occluded (3/40):
- 1 with no occlusion and refluxing
(score 0)
- 2 with a GELEV score of 1b, with only
a narrow lumen remaining without
reflux
we expect an occlusion at 12 M
Summary of the results
Total number of
analgetics
0.7
Days of analgetics 0.9 days
Periflebitis 1.1 days
Ecchymosis score 0.02
Paresthesia 0
Summary of the results
Patient satisfaction 8.9
QOL preop 35.1
QOL postop 1w 38.5
QOL postop 1m 27.0
Painscore d2 2.5
Painscore d5 2.0
Painscore d7 1.6
Painscore d10 0.6
occlusion 37/40 (92.5%)
Conclusion
• low painscore, no ecchymosis, high
quality of life.
• Occlusion rate at six month was
92.5%.
EVRF is a safe and efficient treatment
Thank you!